Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation

JCO Precis Oncol. 2021 Nov:5:849-853. doi: 10.1200/PO.21.00076.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anilides / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Crizotinib / therapeutic use*
  • Drug Resistance, Neoplasm* / genetics
  • Exons / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Mutation
  • Proto-Oncogene Proteins c-met / genetics
  • Pyridines / therapeutic use*

Substances

  • Anilides
  • Antineoplastic Agents
  • Pyridines
  • cabozantinib
  • Crizotinib
  • MET protein, human
  • Proto-Oncogene Proteins c-met